Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
75.98 USD | +0.36% | +0.80% | +6.34% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analyst opinion has improved significantly over the past four months.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
- With a 2024 P/E ratio at 22.76 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
- With an enterprise value anticipated at 4.29 times the sales for the current fiscal year, the company turns out to be overvalued.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+6.34% | 17.77B | B+ | ||
+8.07% | 218B | B | ||
+6.59% | 182B | B- | ||
+11.26% | 132B | B- | ||
+26.57% | 108B | A- | ||
+13.35% | 52.98B | B+ | ||
-0.62% | 47.59B | B+ | ||
-0.93% | 39.96B | A | ||
+11.54% | 39.22B | - | ||
+26.76% | 26.94B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- HOLX Stock
- Ratings Hologic, Inc.